Tolerance of imatinib, dasatinib and nilotinib in the treatment o | 16570
Journal of Drug Metabolism & Toxicology

Journal of Drug Metabolism & Toxicology
Open Access

ISSN: 2157-7609


Tolerance of imatinib, dasatinib and nilotinib in the treatment of chronic leukemia myeloid

International Conference on Toxicogenomics and Drug Monitoring

August 25-27, 2015 Valencia, Spain

Wafa Soudani1, Rachid Djafer1, Hanene Djeddi2, Soraya Boughrira2 and Fatiha Griffi2

1Annaba Medical College, Algeria 2CHU Annaba, Algeria

Scientific Tracks Abstracts: J Drug Metab Toxicol

Abstract :

Background: The Inhibitors of Receivers with Tyrosin Kinase are new therapeutic targets recently explored with an aim of increasing the selectivity of antitumor action, the main aim was to evaluate the tolerance with the Inhibitors of Receivers with Tyrosin Kinase among cancer patients. Method: A retrospective descriptive study was carried out into a series of thirty-three case (33) cancer patients reached of chronic Leukemia myeloid follow-ups on the service of hemato -oncology CHU Annaba during December 2013 to April 2014. Results & Discussion: The study of the tolerance showed that Imatinib: Glivec�?® gave only one case with complications colopathy type and respiratory allergy; with disappearance of the osseous pains and the arterial hypertension obtained with Imatinib: Imatib�?®; what confirms a good tolerance of the specialty of Glivec�?® compared to Imatib�?®. We did not note any complication for Dasatinib and Nilotinib, with reduction in the specific effects (Dasatinib gave 16.67% of the osseous pains, Nilotinib 9.09% of osseous pains and 9.09% of myalgia), reduction in the asthenia (33.33% for Dasatinib and 9.09% for Nilotinib); this testifies to a better tolerance of the new inhibiting molecules of receivers with Tyrosin Kinase Dasatinib and Nilotinib compared to the molecule of reference Imatinib. Conclusion: Through these data we raise the interest of selection of the therapeutic protocols and the importance of a strict monitoring of the undesirable effects of therapeutic targeted in order to ensure better followed therapeutic for the cancer patients.

Biography :

Wafa Soudani received Doctorate on pharmacy from Annaba medical college-Algeria. She has continued study in Algiers medical college- Algeria where she was diplomated at the age 27 years and she become a teacher master assisting in chemical chemistry in Annaba Medical college-Algeria at the age 29 years. After that, she has presented many of papers in a lot of international congress (France, Turkey, and Tunisia) as communications and she have published 4 papers in Journal Annals of Clinical Biology, Journal of Clinical Chemistry Laboratory Medicine and Turkish Journal of Agriculture and Natural Science.